LICENSE AGREEMENT BY AND BETWEEN ASTRAZENECA AB AND ARDELYX, INC. OCTOBER 4, 2012License Agreement • May 19th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations • Delaware
This License Agreement (the “Agreement”) is entered into as of the 4th day of October, 2012 (the “Effective Date”) by and between AstraZeneca AB (publ), a Swedish corporation with corporate identity no. 556011-7482 and a place of business at 431 83 Mölndal, Sweden (“AstraZeneca”) and Ardelyx, Inc., a Delaware corporation having its principal place of business at 34175 Ardenwood Boulevard, Fremont, California United States of America 94555 (“Ardelyx”). Ardelyx and AstraZeneca are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE OPTION AND LICENSE AGREEMENT BY AND BETWEEN SANOFI AND ARDELYX, INC. DATED FEBRUARY 21, 2014License Option and License Agreement • May 19th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations • New York
This License Option and License Agreement (the “Agreement”) is entered into as of the 21 day of February, 2014 (the “Effective Date”) by and between Sanofi, a French corporation with a place of business at 54, rue La Boétie, 75008 Paris, France (“Sanofi”) and Ardelyx, Inc., a Delaware corporation having its principal place of business at 34175 Ardenwood Boulevard, Fremont, California United States of America 94555 (“Ardelyx”). Ardelyx and Sanofi are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NUMBER ONE TO LICENSE AGREEMENT BY AND BETWEEN ASTRAZENECA AB AND ARDELYX, INC. DECEMBER 23, 2013License Agreement • May 19th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations • Delaware
This Amendment Number One to License Agreement (“Amendment One”) is entered into as of the 23rd day of December, 2013 (the “Amendment One Effective Date”) by and between AstraZeneca AB (publ), a Swedish corporation with corporate identity no. 556011-7482 and a place of business at 431 83 Molndal, Sweden (“AstraZeneca”) and Ardelyx, Inc. a Delaware corporation having its principal place of business at 34175 Ardenwood Boulevard, Fremont, California United States of America 94555 (“Ardelyx”). Ardelyx and AstraZeneca are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ARDELYX, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Dated as of June 23, 2011Investors’ Rights Agreement • May 19th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of June 23, 2011 by and among Ardelyx, Inc., a Delaware corporation (the “Company”) formerly known as Nteryx, Inc., Dominique Charmot and Jean Frechet (the “Founders”), the investors listed on Schedule A hereto (each an “Investor” and collectively the “Investors”), and such Investors who may be added to this Agreement as provided herein.
LEASELease • May 19th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations
THIS ACKNOWLEDGEMENT OF PHASE 2 TERM COMMENCEMENT DATE is entered into as of [ ], 20[ ], with reference to that certain Lease (the “Lease”) dated as of August 8, 2008, by NTERYX, INC., a Delaware corporation (“Tenant”), in favor of 34175 ARDENWOOD VENTURE, LLC, a Delaware limited liability company (“Landlord”). All capitalized terms used herein without definition shall have the meanings ascribed to them in the Lease.
FIRST AMENDMENT TO LEASELease • May 19th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 20th day of December, 2012, by and between 34175 ARDENWOOD VENTURE, LLC, a Delaware limited liability company (“Landlord”), and ARDELYX, INC., a Delaware corporation formerly known as Nteryx, Inc. (“Tenant”).
